For years, Novo Nordisk was a discreet and little-known pharmaceutical firm targeted on the world of diabetes. However the whole lot modified with the increase in weight-loss therapies. Due to Ozempic and Wegovy, the Danish firm grew to become probably the most priceless in Europe, even surpassing Nestlé and LVMH.
📉 Nonetheless, in latest months it has misplaced greater than 56% of its inventory market worth. A key alliance in the US was damaged, competitors from Eli Lilly turned fierce, regulators started asking questions… and the magic began to falter.
On this video, we inform you the total story behind the rise and fall of Novo Nordisk, what is occurring with the well-known GLP-1 medicine, and whether or not this inventory market drop is a novel funding alternative… or a traditional market lure.
Try our earlier movies! ⬇️
🔴The BIGGEST INDUSTRIAL FAILURE of the USA?
https://youtu.be/cLRmzfvTGms
🔴Adobe is PLUNGING 40%… Are we going through a brand new KODAK case?
https://youtu.be/Y3ZKjHd_kEA
🔴Can We Compete? Chinese language Firms are Giving Up Earnings
https://youtu.be/u13e1VFNZLk
✉️ Enterprise Enquiries → staff@visualeconomik.com
source